Streetbeat News

Price Targets

CYTK

B. Riley Securities has initiated coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and a price target of $66.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:10 pm

VTYX

Morgan Stanley analyst Vikram Purohit has downgraded Ventyx Biosciences from Overweight to Equal-Weight and lowered the price target from $46 to $6.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:06 pm

ZTO

B of A Securities analyst Fan Tso has downgraded ZTO Express (Cayman) (NYSE:ZTO) from Buy to Neutral and lowered the price target from $34 to $28.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:55 pm

SRAD

Craig-Hallum has reiterated its 'Buy' rating and $18 price target on Sportradar (SRAD).

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:44 pm

UNIT

B of A Securities analyst David Barden has downgraded Uniti Group (NASDAQ:UNIT) from Neutral to Underperform and lowered the price target from $5 to $3.5.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:40 pm

CVCO

Wedbush analyst Jay McCanless has reiterated an Outperform rating on Cavco Industries, Inc. (NASDAQ:CVCO) but lowered the price target from $390 to $380. This follows a 21.7% decline in Cavco's Q2 FY24 revenue to $452 million and a 17% y/y decline in Q2 shipments. The analyst has also lowered FY24E/FY25E EPS and revenue estimates. However, the analyst raised the average price from $99,000 to $102,000, assuming no widespread pricing pressure from Cavco's competitors.

Portfolio Pulse from Shivani Kumaresan

November 07, 2023 | 6:37 pm

DDOG

Needham analyst Mike Cikos maintains a 'Buy' rating on Datadog (NASDAQ:DDOG) and raises the price target from $110 to $125.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:35 pm

BVH

B. Riley Securities analyst Mike Crawford has downgraded Bluegreen Vacations (NYSE:BVH) from Buy to Neutral, while raising the price target from $66 to $75.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:33 pm

KIDS

Needham analyst Mike Matson has maintained a 'Buy' rating on OrthoPediatrics (NASDAQ:KIDS) but lowered the price target from $55 to $37.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:30 pm

VVX

RBC Capital analyst Ken Herbert has maintained an 'Outperform' rating on V2X (NYSE:VVX) but lowered the price target from $62 to $55.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:29 pm